Highlights of weekly biotech stock moves

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was off $1.08 to $16.01 last week after FDA said an NDA for lomitapide to treat homozygous familial hypercholesterolemia (HoFH) would receive a standard review, instead of Priority Review as the company had requested. A 10-month standard review would place the PDUFA date around January 2013. Aegerion also submitted an MAA to EMA.

Astex Pharmaceuticals Inc. (NASDAQ:ASTX) gained $0.06 to $1.88 last week despite FDA's issuance of a complete response letter for an sNDA for Dacogen decitabine to treat acute myelogenous leukemia (AML) in patients 65 and up...